These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 19223507

  • 1. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.
    Sørensen RB, Andersen RS, Svane IM, Engell-Noerregaard L, Hadrup SR, Balslev E, Andersen MH, thor Straten P.
    Clin Cancer Res; 2009 Mar 01; 15(5):1543-9. PubMed ID: 19223507
    [Abstract] [Full Text] [Related]

  • 2. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.
    Suzuki H, Graziano DF, McKolanis J, Finn OJ.
    Clin Cancer Res; 2005 Feb 15; 11(4):1521-6. PubMed ID: 15746055
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    Cancer; 2009 Feb 15; 115(4):800-11. PubMed ID: 19117353
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Wildtype p53-specific antibody and T-cell responses in cancer patients.
    Pedersen AE, Stryhn A, Justesen S, Harndahl M, Rasmussen S, Donskov F, Claesson MH, Pedersen JW, Wandall HH, Svane IM, Buus S.
    J Immunother; 2011 Feb 15; 34(9):629-40. PubMed ID: 21989411
    [Abstract] [Full Text] [Related]

  • 7. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.
    Tanaka Y, Amos KD, Fleming TP, Eberlein TJ, Goedegebuure PS.
    Surgery; 2003 Jan 15; 133(1):74-80. PubMed ID: 12563241
    [Abstract] [Full Text] [Related]

  • 8. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
    Kubuschok B, Neumann F, Breit R, Sester M, Schormann C, Wagner C, Sester U, Hartmann F, Wagner M, Remberger K, Schilling M, Pfreundschuh M.
    Clin Cancer Res; 2006 Feb 15; 12(4):1365-72. PubMed ID: 16489095
    [Abstract] [Full Text] [Related]

  • 9. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.
    Svane IM, Pedersen AE, Nikolajsen K, Zocca MB.
    Vaccine; 2008 Aug 26; 26(36):4716-24. PubMed ID: 18616968
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O, Lupu A, Schmidt S, Condomines M, Belle S, Maier A, Hose D, Neuber B, Moos M, Kleist C, Terness P, Ho AD, Goldschmidt H, Klein B, Hundemer M.
    J Immunother; 2009 Aug 26; 32(6):613-21. PubMed ID: 19483648
    [Abstract] [Full Text] [Related]

  • 17. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
    Maccalli C, Di Cristanziano V, Fodale V, Corsi D, D'Agostino G, Petrangeli V, Laurenti L, Guida S, Mazzocchi A, Arienti F, Perrone MP, Castelli C, Rivoltini L, Zagonel V, Tartaglia M, Parmiani G, Belardelli F.
    Clin Cancer Res; 2008 Nov 15; 14(22):7292-303. PubMed ID: 18974390
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer.
    Egloff AM, Weissfeld J, Land SR, Finn OJ.
    Ann N Y Acad Sci; 2005 Dec 15; 1062():29-40. PubMed ID: 16461786
    [Abstract] [Full Text] [Related]

  • 19. T-cell responses to cyclin B1 are not restricted to p53-overexpressing tumors.
    von Bergwelt-Baildon MS, Shimabukuro-Vornhagen A, Klein-Gonzalez N, Kondo E.
    Clin Cancer Res; 2009 Nov 15; 15(22):7106; author reply 7106-7. PubMed ID: 19903794
    [No Abstract] [Full Text] [Related]

  • 20. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S.
    J Clin Oncol; 2005 Oct 20; 23(30):7536-45. PubMed ID: 16157940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.